Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
1(100.0%)
1Total
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06686082Enrolling By Invitation

A Real-World Study of Biologic Therapy for Subclinical Psoriatic Arthritis

Role: lead

NCT06663943Phase 1Not Yet Recruiting

A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313.

Role: lead

NCT06654817Completed

Efficacy and Safety Evaluation of Anti-CD20 Monoclonal Antibody Combined with Azathioprine and Corticosteroids in the Treatment of Pemphigus Vulgaris

Role: lead

NCT06561256Completed

JAK Inhibitors' Efficacy in Bullous Pemphigoid

Role: lead

NCT06522048Completed

SJS/TEN or Other Cutaneous Adverse Eevents Induced by Immune Checkpoint Inhibitors (ICIs) vs. Non-ICIs

Role: lead

NCT06391996Completed

Biologic Therapy for Generalized Pustular Psoriasis

Role: lead

All 6 trials loaded